Matthew Austin1, Peter J Quesenberry2, Corey E Ventetuolo3, Olin Liang2, John L Reagan4. 1. Division of Hematology and Oncology, Yale University School of Medicine, New Haven, CT. 2. Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI. 3. Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI. 4. Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI. Electronic address: john_reagan@brown.edu.
Abstract
BACKGROUND: Myelofibrosis (MF), a rare disorder characterized by bone marrow fibrosis, has been implicated as a cause of pulmonary hypertension (PH). To date, studies examining this association have not looked at the impact of PH on survival in MF. We examined the relationship between MF and PH by echocardiogram (echo) using a retrospective patient database and examined the influence of PH on overall survival. PATIENTS AND METHODS: In this single-center retrospective chart review, we identified 65 patients with biopsy-proven primary and secondary MF, 31 of whom underwent transthoracic echo. After accounting for chronic obstructive pulmonary disease and left-sided or valvular heart dysfunction, which excluded 6 patients, we identified 14 patients (56%) who had echo evidence of group 5 PH (ie, PH due to unclear or multifactorial mechanisms), 8 with primary MF and 6 with secondary MF. MF patients with PH trended toward being predominantly female, being older, and less often having constitutional symptoms compared to the non-PH cohort. RESULTS: There was no effect of the presence of PH on overall survival in the entire MF cohort or in any subgroup analyzed, including primary MF versus secondary MF and primary MF intermediate risk patients. CONCLUSION: Given the high prevalence of MF-associated PH, there may be a larger role for routine echo screening in MF patients. Further, the underlying association between PH and MF may signify an endothelial plasticity or increased telomerase activity as part of the pathogenesis of MF.
BACKGROUND:Myelofibrosis (MF), a rare disorder characterized by bone marrow fibrosis, has been implicated as a cause of pulmonary hypertension (PH). To date, studies examining this association have not looked at the impact of PH on survival in MF. We examined the relationship between MF and PH by echocardiogram (echo) using a retrospective patient database and examined the influence of PH on overall survival. PATIENTS AND METHODS: In this single-center retrospective chart review, we identified 65 patients with biopsy-proven primary and secondary MF, 31 of whom underwent transthoracic echo. After accounting for chronic obstructive pulmonary disease and left-sided or valvular heart dysfunction, which excluded 6 patients, we identified 14 patients (56%) who had echo evidence of group 5 PH (ie, PH due to unclear or multifactorial mechanisms), 8 with primary MF and 6 with secondary MF. MF patients with PH trended toward being predominantly female, being older, and less often having constitutional symptoms compared to the non-PH cohort. RESULTS: There was no effect of the presence of PH on overall survival in the entire MF cohort or in any subgroup analyzed, including primary MF versus secondary MF and primary MF intermediate risk patients. CONCLUSION: Given the high prevalence of MF-associated PH, there may be a larger role for routine echo screening in MF patients. Further, the underlying association between PH and MF may signify an endothelial plasticity or increased telomerase activity as part of the pathogenesis of MF.
Authors: A Cortelezzi; G Gritti; N Del Papa; M C Pasquini; R Calori; U Gianelli; M Cortiana; G Parati; F Onida; F Sozzi; C Vener; P Bianchi; G L Deliliers Journal: Leukemia Date: 2007-09-13 Impact factor: 11.528
Authors: Kewal Asosingh; Samar Farha; Alan Lichtin; Brian Graham; Deepa George; Micheala Aldred; Stanley L Hazen; James Loyd; Rubin Tuder; Serpil C Erzurum Journal: Blood Date: 2012-06-28 Impact factor: 22.113
Authors: Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Jason M Aliotta; Mandy Pereira; Sicheng Wen; Mark S Dooner; Michael Del Tatto; Elaine Papa; Laura R Goldberg; Grayson L Baird; Corey E Ventetuolo; Peter J Quesenberry; James R Klinger Journal: Cardiovasc Res Date: 2016-03-14 Impact factor: 10.787
Authors: N Gambaryan; F Perros; D Montani; S Cohen-Kaminsky; M Mazmanian; J-F Renaud; G Simonneau; A Lombet; M Humbert Journal: Eur Respir J Date: 2010-09-30 Impact factor: 16.671
Authors: Jason M Aliotta; Mandy Pereira; Ashley Amaral; Arina Sorokina; Zenas Igbinoba; Alexander Hasslinger; Rabih El-Bizri; Sharon I Rounds; Peter J Quesenberry; James R Klinger Journal: Cardiovasc Res Date: 2013-07-18 Impact factor: 10.787
Authors: Jeffrey L Spees; Mandolin J Whitney; Deborah E Sullivan; Joseph A Lasky; Miguel Laboy; Joni Ylostalo; Darwin J Prockop Journal: FASEB J Date: 2007-11-21 Impact factor: 5.191
Authors: Olin D Liang; Eui-Young So; Pamela C Egan; Laura R Goldberg; Jason M Aliotta; Keith Q Wu; Patrycja M Dubielecka; Corey E Ventetuolo; Anthony M Reginato; Peter J Quesenberry; James R Klinger Journal: Cardiovasc Res Date: 2017-11-01 Impact factor: 10.787